The Vascular Effects of Exenatide Versus Metformin in Patients With Pre-Diabetes

NCT00546728 on ClinicalTrials.gov · last registry update 2013-11-08

Finished July 2011, after enrolling 50 people. Primary outcome, as filed: Change in Reactive Hyperemic Index Over the 3-month Treatment Period. exenatide is approved in the US, but not for prediabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P4
Drug: exenatide
Bydureon, Byetta
Sponsor: St. Paul Heart Clinic
Sponsor type: Other
Enrollment: 50
Started: 2007-10
Primary completion: 2011-07 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in Reactive Hyperemic Index Over the 3-month Treatment Period

Conditions studied

Impaired Glucose Tolerance

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.